Passage Bio terminates Gemma collaboration and exits Philadelphia office lease with $2.3M fee

Passage BIO, Inc.

Terminated Gemma Biotherapeutics collaboration covering Huntington's disease and Temporal Lobe Epilepsy programs, effective May 21, 2026.
Termination also eliminates options for four new CNS indications under the July 2024 agreement.
Paid $2.3M to exit 37,000 sq ft office lease (originally expiring Dec 2031); company is remote-only.
Subleases previously covered substantially all of that office space.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Passage BIO, Inc. terminated 2005 Market Street Lease Agreement with Commerce Square Partners – Philadelphia Plaza, L.P. valued at Termination fee of $2.3 million (effective 2026-05-22).

Action: termination
Agreement: lease
Counterparty: Commerce Square Partners – Philadelphia Plaza, L.P.
Value: Termination fee of $2.3 million
Effective: 2026-05-22

Exact text from the filing

On May 22, 2026, the Company and Commerce Square Partners – Philadelphia Plaza, L.P. (the “ Landlord ”) entered into a lease termination agreement (the “ Termination Agreement ”) with respect to that certain lease agreement dated April 10, 2020 between the Company and Landlord (the “ 2005 Market Street Lease Agreement ”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Passage BIO, Inc. terminated Gemma Collaboration Agreement with Gemma Biotherapeutics, Inc. valued at Notice of termination provided on May 21, 2026, effective in accordance with agreement terms (effective 2026-05-21).

Action: termination
Agreement: collaboration
Counterparty: Gemma Biotherapeutics, Inc.
Value: Notice of termination provided on May 21, 2026, effective in accordance with agreement terms
Effective: 2026-05-21

Exact text from the filing

On May 21, 2026, Passage Bio, Inc. (the “ Company ”) provided written notice to Gemma Biotherapeutics, Inc. (“ Gemma ”) of termination of the research, collaboration and license agreement, dated July 31, 2024, by and between Gemma and the Company (as amended, the “ Gemma Collaboration Agreement ”), which termination will be effective in accordance with the terms of the Gemma Collaboration Agreement.

View on SEC.gov

Browse all material agreements →

Passage BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-066956

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.